Introduction {#sec1-1}
============

Giant cell tumor of bone is an aggressive and highly osteolytic bone tumor ([@ref1]). Giant cell tumor of bone is composed of three major cell types including osteoclast-like multinucleated giant cells, spindle-like stromal cells, and monocytic round cells ([@ref2]). Current preferred treatment of giant cell tumor (GCT) consists of limb sparing surgery by means of extended curettage in addition to local adjuvant therapies ([@ref3]). Albeit anatomy and function are preserved with such an approach, local recurrence rates remain high ([@ref4], [@ref5]), thus the importance of developing an understanding of the biology of this tumor and subsequent creation of more effective therapeutic options is greatly emphasized.

MicroRNAs (miRNAs) are a group of endogenously expressed, non-coding small RNAs (20-25 nucleotides in length). MicroRNAs negatively regulate the expression of target mRNAs by suppressing translation or decreasing the stability of mRNAs ([@ref6]). It has been found that miRNAs play crucial roles in many biological processes including cell differentiation, proliferation and apoptosis ([@ref7], [@ref8]). An increasing number of studies have demonstrated that miRNAs can function as oncogenes or tumor suppressors ([@ref9]-[@ref11]). MiR-125b has been identified as a tumor suppressor in many tumors such as bladder cancer, breast cancer and oral squamous cell carcinoma ([@ref12]-[@ref15]). Currently, the role of miR-125b in bone tumor has been explored. miR-125b is significantly down-regulated in Ewing's sarcoma (ES), and overexpression of this miRNA inhibited ES cell proliferation, migration and invasion, blocked cell cycle progression, and induced cell apoptosis ([@ref16]). However, the specific role of miR-125b in GCT remains unknown.

Materials and Methods {#sec1-2}
=====================

Cells and cell culture {#sec2-1}
----------------------

Primary cell cultures were established from GCT patients after obtaining informed consent in accordance with a protocol approved by the Ethics Committee of Central South University (Changsha, China). GCT stromal cells were isolated in culture as previously described ([@ref17]). Human Embryonic Kidney 293 (HEK293) cells were maintained in RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA).

Patient sample collection {#sec2-2}
-------------------------

Twelve pairs of GCT tissues and adjacent normal bone tissues were collected by routine therapeutic surgery after obtaining informed consent in accordance with a protocol approved by the Ethics Committee of Central South University (Changsha, China).

Quantitative RT-PCR analysis {#sec2-3}
----------------------------

The total RNAs were extracted from cells with TRIZOL reagent (Invitrogen). For the detection of miR-125b, RT and PCR reactions were performed by using qSYBR-green-containing PCR kit (Genecopie), and U6 snRNA as an endogenous control for miRNA detection. For PTH1R, RANKL or IL-8 mRNA, cDNA was synthesized from 1 μg of total RNA by means of Reverse Reaction kit according to the manufacturer's instructions (Promega, Madison, WI, USA). Human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an endogenous control. The relative gene expression was calculated using the 2-ddCt method relative to U6 snRNA or GAPDH.

Cell proliferation assays {#sec2-4}
-------------------------

Transfected cells were plated on 12-well or 96-well plates at the desired cell concentrations and the cell proliferation was measured using direct cell counting, MTS-formazan reduction (Promega, USA) and Cell Counting Kit-8 fluids (CCK-8, Dojindo, Mashikimachi, Japan) by absorbance at 450 nm.

Apoptosis analysis {#sec2-5}
------------------

The apoptotic cells were evaluated by Annexin V-FITC and propidium iodine staining (BD, USA) and analyzed with a FACS Calibur instrument (BD, USA). The collected data were analyzed using FlowJosoftware.

Luciferase reporter assay {#sec2-6}
-------------------------

PTH1R 3'-UTR was amplified from human blood genomic DNA, and then was cloned into pMir-Report (Ambion). Yielding mutant constructs, mutations were introduced in potential miR-125b binding sites using the QuikChange site-directed mutagenesis kit (Stratagene). The plasmids of the wild-type or mutant UTR of PTH1R were cotransfected either with miR-125b mimics or negative control (NC) into HEK293 cells using Lipofectamine™ 2000 (Invitrogen). After 48 hr, cells were harvested and assayed using the Dual Luciferase Reporter Assay System (Promega).

Western blot analysis {#sec2-7}
---------------------

Proteins were separated by 10% SDS-PAGE and then transferred to PVDF membranes (Amersham, Buckinghamshire, UK). The membranes were incubated overnight at 4 °C with anti-PTH1R antibody (Sigma) and anti-GAPDH (Sigma) antibody followed by HRP-linked secondary antibodies. incubated overnight at 4 °C with anti-PTH1R antibody (Sigma) and anti-GAPDH (Sigma) antibody followed by HRP-linked secondary antibodies.

Statistical analysis {#sec2-8}
--------------------

Statistical analyses were performed using SPSS 15.0. The difference between groups was analyzed using Student t test when comparing only two groups or one-way analysis of variance when comparing more than two groups. Statistically significant difference was set at *P*\<0.05.

Results {#sec1-3}
=======

MiR-125b is down-regulated in giant cell tumor of bone {#sec2-9}
------------------------------------------------------

First, the expression pattern of miR-125b in GCT was investigated. Expression levels of miR-125b are examined in 12 pairs of GCT tissues and adjacent normal bone tissues by quantitative RT-PCR analysis (qRT-PCR). As shown in [Figure 1](#F1){ref-type="fig"}, miR-125b was significantly down-regulated in GCT tissues compared to the paired non-tumor tissues (*P*=0.006, paired t test).

![The expression of miR-125b in human GCT tissues. miR-125b was detected in 12 GCT patients by qRT-PCR](IJBMS-18-705-g001){#F1}

MiR-125b suppresses GCT stromal cell proliferation and induces cell apoptosis {#sec2-10}
-----------------------------------------------------------------------------

To evaluate the biological significance of miR-125b in the development of GCT, GCT stromal cells were isolated from GCT samples, then transfected with miR-125b, anti-miR-125b or NC lentivirus into these cells. The efficiency was confirmed by real-time PCR ([Figure 2A](#F2){ref-type="fig"}). Then, cell proliferation was measured by using direct cell counting, MTS and CCK-8 assays. Overexpression of miR-125b inhibited cell growth and proliferation, whereas inhibition of miR-125b promoted cell proliferation (*P*\<0.05; [Figure 2B](#F2){ref-type="fig"}, [C](#F2){ref-type="fig"}, [D](#F2){ref-type="fig"}). Furthermore, miR-125b overexpression increased the percentage of apoptotic cells, but knockdown of this miRNA did not significantly change GCT stromal cell apoptosis ration ([Figure 2E](#F2){ref-type="fig"}).

![MiR-125b inhibits GCT stromal cell proliferation and induces cell apoptosis. (A) miR-125b expression was examined by qRT-PCR in GCT stromal cells transfected with negative control (NC), miR-125b or anti-miR-125b lentivirus. (B) Growth assays were performed by direct cell counting. GCT stromal cells were transfected with NC, miR-125b or anti-miR-125b lentivirus. (C, D) The cell proliferative potential was determined in GCT stromal cells by MTS assay (C) and CCK-8 (D) assay. The absorbance at 450 nm was assayed and data were presented as mean±s.d from at least three independent experiments. (E) The apoptotic cells were evaluated by Annexin V-FITC and propidium iodine (PI) staining and analyzed with FACS. Data are presented as mean±SD \**P*\<0.05; \*\* *P*\<0.01](IJBMS-18-705-g002){#F2}

MiR-125b inhibits GCT stromal cell proliferation by targeting PTH1R {#sec2-11}
-------------------------------------------------------------------

Using in silicon prediction programs, PTH1R was identified as a potential target for miR-125b. PTH1R was selected out for its role in osteoclastogenesis and pathogenesis of bone tumor ([@ref17], [@ref18]). To verify whether PTH1R is a direct target of miR-125b, we cloned the wild-type 3'UTR or the mutant (lacking the 7-bp seed sequence) into a luciferase reporter vector. When we cotransfected HEK293 cells with the cloned UTR and miR-125b mimics, we observed that miR-125b overexprssion caused a consistent reduction in luciferase activity for wild type 3'UTR-reporter. Conversely, cotransfection of miR-125b mimics with the mutated form of 3'UTR-reporter resulted in no significant change in luciferase activity ([Figure 3A](#F3){ref-type="fig"}, [B](#F3){ref-type="fig"}), suggesting that miR-125b directly targeted the PTH1R 3'-UTR. In agreement, miR-125b overexpression significantly reduced both mRNA and protein expression for PTH1R in GCTSC cells. Conversely, miR-125b inhibitors transfection increased its mRNA and protein levels ([Figure 3C](#F3){ref-type="fig"}, [D](#F3){ref-type="fig"}). Overexpression of miR-125b also inhibited PTH1R downstream targets such as RANKL and IL-8 expression, whereas knockdown of this miRNA increased RANKL and IL-8 expression ([Figure 3E](#F3){ref-type="fig"}), further indicating that PTH1R is a target of miR-125b in GCT cells.

![PTH1R is a direct target of miR-125b. (A) PTH1R 3'UTR contains one predicted miR-125b binding site. The mutagenic nucleotides are indicated in grey. (B) Dual luciferase reporter assay. HEK293 cells were transfected with wild type 3'UTR-reporter or mutant (Mut) constructs together with miR-125b mimics or negative controls (NC). Relative firefly luciferase expression was normalized to Renilla luciferase. (C, D) The expression levels of PTH1R in GCTSCs transfected with NC, miR-125b or anti-miR-125b lentivirus by qRT-PCR and western blot. (E) qRT-PCR to measure RANKL and IL-8 expression in GCTSCs transfected with NC, miR-125b or anti-miR-125b lentivirus. (F, G and H) PTH1R rescues the suppressive roles of miR-125b in GCTSC proliferation. GCTSCs miR-125b or NC were transfect with or without PTH1R plasmids. Cell proliferation analysis was performed by cell counting (F), MTS assay (G) and CCK-8 assay (H). Data are presented as mean±sd. \**P*\<0.05; \*\* *P*\<0.01](IJBMS-18-705-g003){#F3}

To verify the functional connection between miR-125b and PTH1R, PTH1R were transfected with plamids containing PTH1R gene or empty vector after transfection of miR-125b mimics. As shown in [Figure 3F](#F3){ref-type="fig"}-[H](#F3){ref-type="fig"}, in miR-125b-expressing cells, overxpression of PTH1R rescued growth defects of miR-125b, underlining the specific importance of the PTH1R for miR-125b action. Therefore, our results suggest that the role of miR-125b in the development of GCT, at least in part, depends on its down-regulation of PTH1R pathway.

Discussion {#sec1-4}
==========

MiRNAs comprise approximately 1% of the genome of different species, each of which has hundreds of different conserved or non-conserved targets, making them key players in various cellular processes ([@ref19]). Thus, it is extremely important to understand physiological and disease-associated mechanisms of these small, single-stranded RNAs. Recent studies have revealed a critical role for miRNAs in tumor development and progression, particularly in GCT ([@ref20], [@ref21]). In the present study, we determined that the level of miR-125b expression was significantly lower in GCT than that adjacent non-tumor tissue in our patient cohort. Using in vitro and in vivo assays, we found that miR-125b could inhibit GCT stromal cell proliferation and induce GCTSC apoptosis. Our results are in accordance with other studies, suggesting the tumor suppressor role of miR-125b in cancers, and provide a solid foundation for the utilization of miR125b in anticancer therapy in future.

We next explored the possible targets of miR-125b in GCT through different computational algorithms. Silicon analysis revealed PTH1R as a candidate target of miR-125b. PTH1R was selected out for its role in osteoclastogenesis and pathogenesis of bone tumor ([@ref17], [@ref18], [@ref22], [@ref23]). PTHR1 belongs to a group of transmembrane receptors that bounds with G proteins. PTH/PTHrP binding to PTHR1 results in the activation of pathways in osteoblasts that promote osteoclastogenesis through increasing RANKL ([@ref23]). Previously, a study has shown that PTHrP/PTH1R is constitutively expressed in GCT ([@ref18]). Furthermore, PTHrP/PTH1R pathway can inhibit GCT stromal cell proliferation and induce GCT apoptosis ([@ref19]). Here, PTH1R as a direct target of miR-125b was further confirmed in luciferase activity assays and miR-125b-mediated PTHR1 expression analysis. MiR-125b also inhibited RANKL and IL-8 expression. Importantly, ovexpression of PTH1R rescued growth defects of miR-125b in GCT stromal cells. Our results suggest that miR-125b inhibits cell growth in giant cell tumor by targeting PTH1R.

Conclusion {#sec1-5}
==========

Our findings demonstrate that miR-125b is significantly down-regulated in GCT clinical specimens and acts as a tumor suppressor through suppression of the PTH1R/RANKL signaling pathway by targeting the PTH1R gene. These results may help us understand the molecular mechanism of GCT carcinogenesis, and provide us with a strong rationale to further investigate miR-125b as a potential biomarker and therapeutic target for GCT.
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